• Note: risperidone orodispersible tablets should only be used in situations where the plain tablets are unsuitable.

Approved for:

• schizophrenia in people aged 15 to 17 years in line with NICE.
• moderate to severe manic episodes in young people aged 13 and older with bipolar I disorder NICE.
• to be used in accordance with NICE criteria.

Aripriprazole 10mg & 15mg orodispersible tablets are approved for doses over 5mg for those patients who have difficulty swallowing.

Aripiprazole 1mg in 1ml oral solution is only for doses of 5mg or less, or when titrating patients on doses of increments of less than 5mg, in patients who have difficulty swallowing tablets. NB: aripiprazole oral solution is significantly more cost effective than oral solution sugar free

Note: Aripiprazole 7.5mg/ml IM Injection is approved for use in rapid tranquilisation in patients with acute psychosis.  NTW use only.

• First choice in patients with treatment-resistant schizophrenia. 

• Contact CNTW Pharmacy for continued supply on admission and discharge
• TEWV Clozapine Information & Guidance

• 18.5mg, 37mg and 74mg tablets
• Approved for the treatment of schizophrenia in adults and adolescents aged 13 years and over 
• Approved Unlicensed indications: 
  •  Bipolar Depression: as 2^nd line option for monotherapy when 1^st line therapies have not been effective or tolerated: quetiapine, olanzapine-fluoxetine combination, or olanzapine monotherapy.
  •  Major depressive disorder with mixed features, as an alternative option where 1^st line therapies have not been effective or tolerated.

• Olanzapine orodispersible tablets should only be used in situations where the plain tablets are unsuitable. 

• Olanzapine orodispersible tablets and injection are also approved for 2nd/3rd- line use in the management of delirium in critical care patients unlicensed indication. 

•  10 mg injection 
  • for rapid control of agitation and disturbed behaviours in patients with schizophrenia or manic episode, when oral therapy is not appropriate.
  • for delirium at end of life 

• 210mg, 300mg & 405mg powder and solvent for suspension for long-acting injection (as olanzapine embonate monohydrate) 
  
  
  • approved for the treatment of schizophrenia in adults within secure psychiatric services
  
  
  

• 25mg, 100mg, 150mg 200mg & 300mg tablets 


• 50mg, 200mg, 300mg & 400mg prolonged release tablets  
  
  
  
  
  • Prolonged release tablets are approved for use in patients who require an outside carer to administer their medicines, and for short term use when rapid dose titration is considered important e.g. where its use might avoid the need to admit the patient to hospital.
  
  
  
  


• Quetiapine 20mg/ml Oral Suspension (Rosemont) - CNTW only